ANAHEIM, Calif., Sept. 1, 2011 /PRNewswire/ -- Please replace the release dated August 24, 2011 with the following updated version. First graph, second and third sentences added and should read: The Company will provide attendees an updated investor presentation, which will be filed in a Form 8K with the SEC after the close of the U.S. financial markets on Friday, September 9, 2011. This presentation will also be available at http://ir.questcor.com/sec.cfm. Second graph, second and third sentences updated and should read: Don M. Bailey, President and Chief Executive Officer, and members of the executive management team are scheduled to provide an overview of the Company in an "unplugged" fireside chat and Q&A session on Wednesday, September 14, 2011 at 8:00 a.m. ET. A live audio only webcast and subsequent archived replay of the discussion will be accessible at http://ir.questcor.com/events.cfm.
The full updated release reads:
Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that members of its executive management team will present at the following investor conferences in early September. The Company will provide attendees an updated investor presentation, which will be filed in a Form 8K with the SEC after the close of the U.S. financial markets on Friday, September 9, 2011. This presentation will also be available at http://ir.questcor.com/sec.cfm.
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, for which Acthar is approved as both a maintenance therapy and to treat exacerbations. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information, please visit www.questcor.com.
|SOURCE Questcor Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved